Elanco launches Befrena in U.S. canine dermatology market
Bottom line
Elanco has begun a phased U.S. launch of Befrena (tirnovetmab), a USDA-approved anti-IL-31 monoclonal antibody injection for dogs with allergic dermatitis and atopic dermatitis. The company says the in-clinic injectable starts controlling itch within 24 hours and is labeled for 6 to 8 weeks of relief, with no age or weight restrictions. Befrena was approved by USDA on December 31, 2025, and enters a canine dermatology market long led by Zoetis’ lokivetmab, giving veterinarians another biologic option for allergic itch management. (elanco.com)
Why it matters: For veterinary professionals, Befrena adds a new injectable choice in a high-volume category where adherence, speed of relief, and revisit intervals all affect case management and clinic workflow. USDA’s product summary shows field efficacy data in 213 client-owned dogs and safety data in 400 dogs, with adverse events generally consistent with control; the summary also notes monoclonal antibodies can induce anti-drug antibodies that may affect response. Elanco is positioning Befrena alongside Zenrelia as part of a broader dermatology push, and recent manufacturing expansion in Kansas suggests the company is preparing for sustained biologics demand. (aphis.usda.gov)
What to watch: Watch for broader clinic availability, real-world durability versus existing anti-IL-31 options, and whether Elanco can ease supply constraints as it says unconstrained Befrena levels are expected in early 2027. (investor.elanco.com)
Elanco is expanding its canine dermatology lineup with the phased U.S. launch of Befrena (tirnovetmab), a USDA-approved anti-IL-31 monoclonal antibody injection for allergic dermatitis and atopic dermatitis in dogs. The company says the product starts controlling itch within 24 hours, is administered in clinic, and offers a labeled 6 to 8 week dosing interval. Befrena was approved on December 31, 2025, and launched on May 18, 2026, giving veterinarians a new entrant in a major itch-management category. (elanco.com)
The launch builds on Elanco’s broader dermatology strategy. In its USDA approval announcement, the company framed Befrena as its second dermatology product approved in less than 18 months, following Zenrelia, and as part of a push to strengthen its position in the estimated $1.3 billion U.S. canine dermatology market. Befrena is also Elanco’s second USDA-approved monoclonal antibody in pet health, after Trutect for canine parvovirus. (elanco.com)
Regulatory filings add more detail than the launch materials alone. APHIS lists Befrena under product code 958005 for canine use, with tirnovetmab targeting interleukin-31. USDA’s product-summary PDF describes an IL-31-induced pruritus model in 40 dogs and a field study in 213 client-owned dogs across 14 practices. In that field study, 69% of product-treated dogs completed the 56-day study versus 51% of controls, and withdrawals for lack of efficacy or need for prohibited medication were lower in the treatment group by Day 14 and through the rest of follow-up. A separate safety study covered 400 dogs treated every six weeks, with adverse events described as generally consistent between investigational product and control groups. (aphis.usda.gov)
The commercial positioning is equally important. Elanco says Befrena has no age or weight restrictions and contrasts its 6 to 8 week interval with the 4 to 8 week interval of the current incumbent, lokivetmab. AAHA’s coverage noted Befrena becomes the second injectable monoclonal antibody for canine allergic dermatitis in the U.S. and reported common adverse events in studies included dermatitis and pyoderma, which were also seen in placebo-treated dogs. AAHA also noted the safety data’s warning that anti-drug antibodies may reduce response or trigger immune-mediated adverse reactions. (elanco.com)
Industry reaction so far has been cautiously positive, though much of it comes from Elanco-linked early users. In Elanco’s launch materials, Dr. Tom Lewis, a veterinary dermatologist and consultant to the company, said Befrena would become “a very important treatment option” for many allergic dogs, while Dr. Jason Pieper of Iowa State said he was “very optimistic” after early cases, including one dog that had failed multiple other atopic dermatitis treatments. dvm360’s recent monoclonal antibody Q&A with Elanco’s Jennifer Miller, DVM, also framed tirnovetmab as part of a broader wave of targeted biologics moving into veterinary medicine. Those comments are useful context, but they should be read with the disclosed consulting relationships in mind. (elanco.com)
Why it matters: For veterinary teams, Befrena could matter less as a headline launch than as a practical new tool in a crowded, compliance-sensitive dermatology workflow. A longer labeled dosing interval may reduce visit frequency for some patients, while the in-clinic administration model can support adherence and follow-up. At the same time, clinicians will want to weigh where Befrena fits relative to established options, including other anti-IL-31 biologics and oral therapies, especially for dogs with recurrent pyoderma, multimodal treatment plans, or prior biologic exposure. Because Befrena is regulated by USDA as a veterinary biologic rather than FDA as a conventional drug, some clinicians and pet parents may also need education on what that pathway means in practice. (elanco.com)
Manufacturing may become part of the story, too. On August 26, 2026, Elanco said it had completed a 25,000-square-foot expansion at its Elwood, Kansas, facility, where Befrena and Trutect are made. The company said demand for Befrena has been running at twice expectations and that the expansion is intended to help ramp capacity, with unconstrained supply anticipated in early 2027. That suggests uptake may be outpacing initial forecasts, but it also means some clinics may still encounter uneven availability in the near term. (investor.elanco.com)
What to watch: The next signals will be real-world durability, repeat-dose experience, clinic pricing and access, and whether Elanco’s manufacturing ramp translates into broader availability before the 2027 timeline it has outlined. (investor.elanco.com)